Regulus Therapeutics Inc (RGLS) — Capital Reinvestment Ratio

Latest as of December 2020: 0.07x

Regulus Therapeutics Inc (RGLS) has a Capital Reinvestment Ratio of 0.07x as of December 2020, meaning it reinvests 0% of its operating cash flow ($3.19 Million) in capital expenditures ($237.00K). Check tangible net worth ratio of Regulus Therapeutics Inc to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.07x
Capex / Operating Cash Flow

Operating Cash Flow

$3.19 Million
USD

Capital Expenditures

$237.00K
USD

Data as of

Dec 2020
Most recent filing

Regulus Therapeutics Inc Capital Reinvestment Ratio (2010–2010)

This chart tracks Regulus Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Regulus Therapeutics Inc operating cash flow efficiency.

Annual Capital Reinvestment Ratio for Regulus Therapeutics Inc (2010–2010)

Year-by-year Capital Reinvestment Ratio for Regulus Therapeutics Inc from 2010 to 2010. See Regulus Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2010 0.20x $12.31 Million $2.42 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow